Company Overview - SOPHiA GENETICS is a cloud-native software company focused on data-driven medicine, utilizing AI to enhance patient care for cancer and rare disorders globally [3] - The company developed the SOPHiA DDM™ Platform, which analyzes complex multimodal data to provide real-time, actionable insights for hospitals, laboratories, and biopharma institutions [3] Financial Results Announcement - SOPHiA GENETICS will release its financial results for Q2 of fiscal year 2024 before U.S. markets open on August 6, 2024 [1] - A conference call to discuss the financial results and business outlook will take place at 8:00 a.m. EDT / 2:00 p.m. CET on the same day [1] Investor Relations - The conference call will be available via live webcast on the SOPHiA GENETICS Investor Relations Website, with a replay accessible after the event [2]

Core Viewpoint - SOPHiA GENETICS held its annual general meeting of shareholders, where all proposals were adopted, reflecting strong shareholder support [1][5]. Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on expanding access to data-driven medicine using AI to provide care for patients with cancer and rare disorders globally [6]. - The company has developed SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions [6]. Shareholder Engagement - The company expressed gratitude to shareholders for their votes and commitment, indicating a positive relationship with its investor base [3]. - Detailed voting results from the AGM will be published on the company's website and filed with the U.S. Securities and Exchange Commission [5].

Core Viewpoint - SOPHiA GENETICS has launched a new Residual Acute Myeloid (RAM) Application to enhance measurable residual disease (MRD) testing, aimed at improving cancer monitoring and relapse prevention [1][2] Group 1: Product Features and Capabilities - The SOPHiA DDM™ RAM Solution utilizes next-generation sequencing (NGS) for MRD testing, capable of detecting one cancer cell among 10,000 cells, with a variant allele frequency (VAF) sensitivity down to 0.01% [2] - The application supports longitudinal variant monitoring, allowing visualization of the mutational landscape for each patient over time, and includes customizable reporting features for comprehensive MRD reports [8] - The solution will continuously improve its machine learning algorithms to provide accurate MRD results within four days [9] Group 2: Market Context and Importance - Acute Myeloid Leukemia (AML) accounts for about 1% of all cancers globally and has a high relapse rate, with over 50% of patients relapsing within three years of achieving complete remission [6] - MRD solutions are critical for informing post-remission therapy and detecting early relapse, serving as a primary endpoint in clinical trials to enhance patient outcomes [6][7] - The introduction of the RAM Solution addresses a significant unmet medical need in AML treatment, potentially transforming clinical research through improved tracking of individual mutations over time [7]

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of further ...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution ...

Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine and is a leader in the field [5] - The company has developed the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights for hospitals, laboratories, and biopharma institutions globally [5] Industry Context - Cancer is the second most common cause of death in Brazil, with an estimated 704,000 new cancer cases expected between 2023 and 2025 [2] - Blood cancers rank as the fifth most common type of cancer worldwide [2] - Instituto Mário Penna, a major oncology service provider in Brazil, has implemented the SOPHiA DDM™ Platform to enhance its testing capabilities and improve data-driven treatment plans for blood-related cancers [2][3] Technological Advancements - The SOPHiA DDM™ Platform utilizes next-generation sequencing (NGS) to identify key variants from various sample types, facilitating rapid and accurate detection of disease-associated variants [3] - The platform is designed to compute a wide array of genomic variants and continuously improves its machine learning algorithms for better detection of rare and challenging cases [4] - Results from the SOPHiA DDM™ Platform are nearly 100 percent reproducible, ensuring consistent and reliable sequencing data [4]

"Precision medicine makes novel therapies for cancer treatment possible," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "The implementation of the SOPHiA DDM™ Platform will help Klinikum Klagenfurt am Wörthersee produce reliable insights from its testing while saving time and valuable resources." The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland, May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cl ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $15.8 million, representing a 13% increase from $14 million in Q1 2023, with analysis volume approximately 84,000, up 9% year-over-year [8][58] - Adjusted operating loss improved 13% year-over-year to $14.1 million compared to $16.2 million in Q1 2023 [18][79] - Gross profit for Q1 2024 was $10.4 million, a 7% increase from $9.7 million in Q1 2023, with a gross margin of 65.9% [75] Business Line Data and Key Metrics Changes - Clinical bookings grew over 30% year-over-year, with 27 new logos signed in Q1, up from 18 in the prior year [13][63] - Oncology applications outperformed rare and inherited disorders, driven by strength in solid tumor testing [66][140] - The pipeline for the clinical business grew over 50% year-over-year, while the biopharma pipeline more than doubled [71] Market Data and Key Metrics Changes - In the U.S., analysis volume grew 34% year-over-year, and revenue increased by 27% [25] - EMEA and Latin America experienced the softest growth during Q1, partially offset by significant strength in North America and Asia-Pacific, which grew at 44% and 39%, respectively [59][60] - Major wins in Asia-Pacific included partnerships in India and South Korea, expanding the company's footprint in these regions [26][27] Company Strategy and Development Direction - The company aims to capitalize on growing demand in biopharma and has developed an action plan to recover revenue in the latter half of the year [16][72] - SOPHiA GENETICS is focused on expanding access to data-driven medicines using AI, with a goal of achieving profitability in the next two-plus years [20][94] - The company has entered into a $50 million debt financing agreement to provide additional capital flexibility for growth strategies, including potential acquisitions [57][89] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong back half of 2024, citing improved consumption levels and strong bookings [17][83] - The company reaffirmed its full-year revenue guidance for 2024 of $78 million to $81 million, indicating a growth of 25% to 30% year-on-year [84] - Management noted that the recent proposed LDT regulations by the FDA could ultimately benefit the company by increasing demand for testing [105][111] Other Important Information - The company reported a cash burn of $19.5 million for Q1 2024, up from $16.8 million in the prior year, attributed to unfavorable FX translation [81] - Cash and cash equivalents were approximately $103.7 million as of March 31, 2024 [82] Q&A Session Summary Question: Can you talk about the revenue rate this year and your confidence in hitting full-year guidance? - Management highlighted strong bookings and utilization trends in March and April, expecting these to fuel growth in the coming quarters [98][100] Question: Do you anticipate any impact on testing volumes due to the proposed LDT regulations by the FDA? - Management welcomed the regulations, believing they will create trust and increase demand among large academic centers and reference labs [105][107] Question: What proportion of new logos are incorporating emerging sequencing platforms? - Management noted that while Illumina remains dominant, there is increasing adoption of other sequencing technologies, particularly in regions outside the U.S. [116][118] Question: Does the new debt financing increase M&A optionality? - Management indicated a willingness to consider acquisitions that align with their growth strategy while remaining financially disciplined [119][125]

:°: SOPHiA ·°·: GENETICS™ No offer to sell or buy Market and industry data © SOPHiA GENETICS 2024 3 4 © SOPHiA GENETICS 2024 For decades, health data has been produced in silos © SOPHiA GENETICS 2024 SOPHiA DDM™ is a decentralized analytics platform which computes © SOPHiA GENETICS 2024 $25B $15B Generating insights from multimodal data to help Clinicians with screening, early detection, diagnosis, therapy selection, and monitoring The decentralized, cloud-based analytics platform at the center of it all No ...

SOPHiA GENETICS SA (SOPH) closed the last trading session at $5.05, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.33 indicates a 65% upside potential.The average comprises three short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.53. While the lowest estimate indicates an increase of 38.6% from the current price leve ...